Companies › Cell Energy Life Sciences Group
1 active drug program in 2 registered trials: 2 Phase 1; Infectious disease, Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| mesenchymal stem cell (umbilical cord derived MSCs) Cell therapy with mesenchymal stem cells | – | Phase 1 | AIDS; COVID-19 Infection | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05939167 | mesenchymal stem cell (umbilical cord derived MSCs) | Phase 1 | AIDS | Infectious disease | Jul 2027 |
| NCT04565665 | mesenchymal stem cell (umbilical cord derived MSCs) | Phase 1 | COVID-19 Infection | Oncology | Oct 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.